Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index, and 2 are not checked yet; 27 of the 47 sources its claims cite were checked for support.

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Open access

Published version of a preprint

Abstract

Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4

Verified 2026-10-06 · 2 references not checked yet

Overview

CoChat Summary

TL;DR

In the phase I/II KRYSTAL-1 trial, adagrasib plus cetuximab produced an ORR of 34.0% by BICR and median OS of 15.9 months in 94 heavily pretreated patients with KRASG12C-mutated unresectable or metastatic colorectal cancer, with no new safety signals. Exploratory ctDNA analyses showed 83% baseline KRASG12C concordance and frequent acquired RTK/MAPK alterations at end of therapy.

Key findings

  • Among 94 patients, BICR-assessed ORR was 34.0% (95% CI, 24.6–44.5), DCR was 85.1% (95% CI, 76.3–91.6), median DOR was 5.8 months (95% CI, 4.2–7.6), median PFS was 6.9 months (95% CI, 5.7–7.4), and median OS was 15.9 months (95% CI, 11.8–18.8). Investigator-assessed ORR was 42.6% (95% CI, 32.4–53.2).
  • In the separate adagrasib monotherapy cohort, BICR ORR was 21.4% (95% CI, 10.3–36.8), median DOR was 15.2 months (95% CI, 2.8–not evaluable), median PFS was 4.1 months (95% CI, 2.8–6.5), and median OS was 12.2 months (95% CI, 8.1–15.2).
  • Grade 3–4 TRAEs occurred in 27.7% of patients; there were no grade 5 TRAEs. Most frequent TRAEs were nausea (60.6%), vomiting (51.6%), diarrhea (48.9%), and dermatitis acneiform (47.9%). TRAEs led to adagrasib dose reduction in 29.8%, cetuximab dose reduction in 6.4%, and cetuximab discontinuation in 8.5%; no TRAEs led to adagrasib discontinuation.
  • Baseline KRASG12C ctDNA/tissue concordance was 83% (69/83). ORR was 39% when KRASG12C was detected in ctDNA versus 14% when not detected. At C4D1, 12/15 (80%) phase I patients had ≥90% decrease in KRASG12C ctDNA, with responses in 67% (8/12) of those versus 33% (1/3) with <90% clearance. Acquired alterations at EOT were found in 25/34 (74%) patients, including secondary KRAS mutations in 41%, KRAS amplification in 29%, RTK amplifications/fusions in 35%, EGFR amplification in 9%, and other MAPK gene mutations/fusions in 38%.

Methods

  • Open-label, nonrandomized, multicenter, multiple-expansion cohort phase I/II study (KRYSTAL-1). Patients received adagrasib 600 mg orally twice daily plus cetuximab intravenously weekly (400 mg/m2 loading then 250 mg/m2) or every 2 weeks (500 mg/m2) until progression, unacceptable toxicity, consent withdrawal, or death.
  • The pooled combination cohort included 94 patients with previously treated, histologically confirmed, unresectable or metastatic KRASG12C-mutated colorectal cancer and ECOG PS 0–1; median age was 57 years, median prior lines of systemic therapy was 3 (range, 1–9), and all had prior fluoropyrimidine. Data cutoff was June 30, 2023; median follow-up was 11.9 months.
  • Primary endpoint was safety for phase I and confirmed ORR by BICR per RECIST v1.1 for phase II. Secondary endpoints included DOR, PFS, OS, and safety. DOR, PFS, and OS were estimated by Kaplan–Meier; ORR CIs used Clopper–Pearson. Exploratory ctDNA analyses used droplet digital PCR for KRASG12C kinetics and targeted hybrid capture NGS for acquired alterations at end of therapy.

Limitations

  • The paper states the study was nonrandomized and open-label with no comparator arm, so causality and comparative efficacy cannot be established. It also notes the high proportion of lung metastases (71.3%) versus liver metastases (63.8%) and that all enrolled patients had MSS tumors, so efficacy in MSI-H/dMMR KRASG12C-mutated colorectal cancer could not be specifically tested.
  • The paper states that ctDNA kinetics data were collected only in the phase I cohort and are not available for phase II; the ctDNA clearance and acquired alteration analyses are exploratory. It also notes there are no prospective data for continuing treatment beyond RECIST progression, which remains investigational.
  • Evident from the text: the pooled analysis combines phase I and phase II cohorts with different median follow-up durations (30.0 vs. 10.0 months) and different cetuximab schedules, and some subgroup analyses were omitted because of small patient numbers (fewer than five in a subgroup category).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-24-0217

Cites

28 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Efficacy outcomes with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC. A, Best change in tumor volume from baseline (n = 86; excludes eight patients without any postbaseline scans). B, Treatment duration (n = 32; only subjects with tumor response are displayed). C, Changes from baseline in sum of target lesion diameters over time for patients with tumor response. D, PFS. E, OS. Data as of June 30, 2023 (median follow-up: 11.9 months). Responses and PFS assessed by BICR per RECIST version 1.1. aOnly patients with objective tumor responses are displayed (n = 32). bTime to first maintained dose reduction due to any cause. BICR, blinded-independent central review; BID, twice daily; CI, confidence interval; CRC, colorectal cancer; DOR, duration of response; OS, overall survival; PFS, progression-free survival; QD, once daily.
Figure 1. Efficacy outcomes with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC. A, Best change in tumor volume from baseline (n = 86; excludes eight patients without any postbaseline scans). B, Treatment duration (n = 32; only subjects with tumor response are displayed). C, Changes from baseline in sum of target lesion diameters over time for patients with tumor response. D, PFS. E, OS. Data as of June 30, 2023 (median follow-up: 11.9 months). Responses and PFS assessed by BICR per RECIST version 1.1. aOnly patients with objective tumor responses are displayed (n = 32). bTime to first maintained dose reduction due to any cause. BICR, blinded-independent central review; BID, twice daily; CI, confidence interval; CRC, colorectal cancer; DOR, duration of response; OS, overall survival; PFS, progression-free survival; QD, once daily.CC BY-NC-ND · PubMed Central
Figure 2. Subgroup analyses of ORR (in FAS per BICR) for patients with KRASG12C-mutated unresectable or metastatic CRC receiving adagrasib plus cetuximab. Data as of June 30, 2023 (median follow-up: 11.9 months). BICR, blinded-independent central review; CI, confidence interval; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS, full analysis set; ORR, objective response rate.
Figure 2. Subgroup analyses of ORR (in FAS per BICR) for patients with KRASG12C-mutated unresectable or metastatic CRC receiving adagrasib plus cetuximab. Data as of June 30, 2023 (median follow-up: 11.9 months). BICR, blinded-independent central review; CI, confidence interval; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS, full analysis set; ORR, objective response rate.CC BY-NC-ND · PubMed Central
Figure 3. KRAS G12C ctDNA clearance in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC receiving adagrasib plus cetuximab (n = 15). Response according to BICR. BICR, blinded independent central review; C, cycle; CRC, colorectal cancer; ctDNA, circulating tumor DNA; D, day; ND, not detected.
Figure 3. KRAS G12C ctDNA clearance in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC receiving adagrasib plus cetuximab (n = 15). Response according to BICR. BICR, blinded independent central review; C, cycle; CRC, colorectal cancer; ctDNA, circulating tumor DNA; D, day; ND, not detected.CC BY-NC-ND · PubMed Central
Figure 4. Acquired genomic alterations in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC receiving adagrasib plus cetuximab; alterations present at EOT, that were not present at baseline. CNA, copy number alteration; EOT, end of therapy; SNV, single nucleotide variant.
Figure 4. Acquired genomic alterations in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC receiving adagrasib plus cetuximab; alterations present at EOT, that were not present at baseline. CNA, copy number alteration; EOT, end of therapy; SNV, single nucleotide variant.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

14 Valid · 1 Not valid · 9 Not checked · 59 Own results and interpretations

37 more claims · 4 with their cited sources checked

Create a free account to see all 83 claims and to verify the 20 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 30 references

Cited by

See all 146

Metadata

Authors
Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., Cruz-Correa, M., Anderes, K., Velastegui, K., Yan, X., Der-Torossian, H., Klempner, S. J., & Kopetz, S. E.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Wisconsin–Madison (US)
  • Tennessee Oncology (US)
  • 4Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, Arizona.
  • Mary Crowley Cancer Research Center (US)
  • Cleveland Clinic (US)
  • NYU Langone Health (US)
  • 8Department of Research, Oncology Consultants PA, Houston, Texas.
  • 9Department of Medical Oncology, Texas Oncology – Baylor Charles A. Sammons Cancer Center, Dallas, Texas.
  • 10Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • 11PanOncology Trials, San Juan, Puerto Rico.
  • 12Mirati Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb Company, San Diego, California.
  • Massachusetts General Hospital (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Yaeger, Rona
  • Uboha, Nataliya V.
Venue
Cancer Discovery
Published
2024-04-08
Volume
14
Issue
6
Pages
982-993
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4394566874
Cited by
139
References
30
Citations by year
2026: 59 · 2025: 65 · 2024: 15
FWCI
23.68
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • Mirati Therapeutics
  • National Institutes of Health (P30 CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
adagrasib, cetuximab, KRAS G12C mutation, metastatic colorectal cancer, KRAS inhibitors, anti-EGFR monoclonal antibody, objective response rate, progression-free survival, overall survival, treatment-related adverse events, circulating tumor DNA, acquired drug resistance, previously treated patients
MeSH terms
Cetuximab, Acetonitriles, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Piperazines, Pyrimidines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-24-0217
The paper
Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., Cruz-Correa, M., Anderes, K., Velastegui, K., Yan, X., Der-Torossian, H., Klempner, S. J., & Kopetz, S. E. (2024). Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-24-0217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.